JP6012726B2 - 脆弱ｘ症候群の治療用組成物 - Google Patents

脆弱ｘ症候群の治療用組成物 Download PDF

Info

Publication number
JP6012726B2
JP6012726B2 JP2014518000A JP2014518000A JP6012726B2 JP 6012726 B2 JP6012726 B2 JP 6012726B2 JP 2014518000 A JP2014518000 A JP 2014518000A JP 2014518000 A JP2014518000 A JP 2014518000A JP 6012726 B2 JP6012726 B2 JP 6012726B2
Authority
JP
Japan
Prior art keywords
mice
fxs
fmr1
chloro
bkca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014518000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518255A5 (enExample
JP2014518255A (ja
Inventor
ブリオー，シルヴァン
パーシェ，オリヴィエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Regional D'orleans
Universite d Orleans UFR de Sciences
Original Assignee
Centre Hospitalier Regional D'orleans
Universite d Orleans UFR de Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional D'orleans, Universite d Orleans UFR de Sciences filed Critical Centre Hospitalier Regional D'orleans
Publication of JP2014518255A publication Critical patent/JP2014518255A/ja
Publication of JP2014518255A5 publication Critical patent/JP2014518255A5/ja
Application granted granted Critical
Publication of JP6012726B2 publication Critical patent/JP6012726B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014518000A 2011-06-27 2012-06-19 脆弱ｘ症候群の治療用組成物 Active JP6012726B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11171532A EP2540295A1 (en) 2011-06-27 2011-06-27 Compositions for the treatment of Fragile X syndrome
EP11171532.2 2011-06-27
PCT/IB2012/053089 WO2013001412A1 (en) 2011-06-27 2012-06-19 Compositions for the treatment of fragile x syndrome

Publications (3)

Publication Number Publication Date
JP2014518255A JP2014518255A (ja) 2014-07-28
JP2014518255A5 JP2014518255A5 (enExample) 2015-07-16
JP6012726B2 true JP6012726B2 (ja) 2016-10-25

Family

ID=44840530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014518000A Active JP6012726B2 (ja) 2011-06-27 2012-06-19 脆弱ｘ症候群の治療用組成物

Country Status (8)

Country Link
US (1) US10435366B2 (enExample)
EP (2) EP2540295A1 (enExample)
JP (1) JP6012726B2 (enExample)
DK (1) DK2723336T3 (enExample)
ES (1) ES2797395T3 (enExample)
PL (1) PL2723336T3 (enExample)
PT (1) PT2723336T (enExample)
WO (1) WO2013001412A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
AU2014233048B2 (en) * 2013-03-15 2019-01-03 The Children's Hospital Of Philadelphia Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders
WO2016128771A1 (en) 2015-02-13 2016-08-18 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation
WO2018157046A1 (en) 2017-02-24 2018-08-30 Ovid Therapeutics Inc. Methods of treating seizure disorders
EP3727587A4 (en) * 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
US20020045566A1 (en) * 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
JP2005507853A (ja) * 2001-02-20 2005-03-24 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用
JP2004531483A (ja) * 2001-02-20 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャネルのモジュレーターとしてのフルオロオキシンドール誘導体
FR2857452B1 (fr) * 2003-07-11 2005-09-30 Univ Rabelais Francois Test de depistage de l'autisme, methode de selection de patients repondant audit test et utilisation des medicaments activateurs de canaux bkca pour le traitement de ladite maladie
DE102004053673A1 (de) * 2004-11-03 2006-05-04 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massendurchflusses eines Mediums
EP2433635A1 (en) 2006-11-10 2012-03-28 Massachusetts Institute Of Technology PAK Modulators
US20100316678A1 (en) * 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome

Also Published As

Publication number Publication date
EP2723336B1 (en) 2020-04-08
US20140221450A1 (en) 2014-08-07
ES2797395T3 (es) 2020-12-02
PT2723336T (pt) 2020-07-14
US10435366B2 (en) 2019-10-08
EP2723336A1 (en) 2014-04-30
JP2014518255A (ja) 2014-07-28
EP2540295A1 (en) 2013-01-02
PL2723336T3 (pl) 2020-10-19
WO2013001412A1 (en) 2013-01-03
DK2723336T3 (da) 2020-06-29

Similar Documents

Publication Publication Date Title
JP6012726B2 (ja) 脆弱ｘ症候群の治療用組成物
Kinghorn et al. A Drosophila model of neuronopathic Gaucher disease demonstrates lysosomal-autophagic defects and altered mTOR signalling and is functionally rescued by rapamycin
Cuddy et al. Stress-induced cellular clearance is mediated by the SNARE protein ykt6 and disrupted by α-Synuclein
Tărlungeanu et al. Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder
Andre et al. Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies
Song et al. Schizophrenia-like features in transgenic mice overexpressing human HO-1 in the astrocytic compartment
Borie et al. Correction of vasopressin deficit in the lateral septum ameliorates social deficits of mouse autism model
Sethna et al. From FMRP function to potential therapies for fragile X syndrome
Maddaloni et al. Serotonin depletion causes valproate-responsive manic-like condition and increased hippocampal neuroplasticity that are reversed by stress
Bavley et al. Rescue of learning and memory deficits in the human nonsyndromic intellectual disability cereblon knock-out mouse model by targeting the AMP-activated protein kinase–mTORC1 translational pathway
Chatterjee et al. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice
Kapell et al. Neuron-oligodendrocyte potassium shuttling at nodes of Ranvier protects against inflammatory demyelination
Oginsky et al. Alterations in the cholinergic system of brain stem neurons in a mouse model of Rett syndrome
Paribello et al. Melatonin and aggressive behavior: A systematic review of the literature on preclinical and clinical evidence
Xiong et al. Thymol improves autism-like behaviour in VPA-induced ASD rats through the Pin1/p38 MAPK pathway
Chong et al. Lrrc7 mutant mice model developmental emotional dysregulation that can be alleviated by mGluR5 allosteric modulation
Hamasu et al. Intracerebroventricular injection of L-proline and D-proline induces sedative and hypnotic effects by different mechanisms under an acute stressful condition in chicks
Xue et al. CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation
Cheng et al. Rasd2 mediates acute fasting-induced antidepressant-like effects via dopamine D2 receptor activation in ovariectomized mice
Dierssen et al. Building the future therapies for down syndrome: The third international conference of the T21 research society
Foltran et al. Neurochemical, behavioral, and neurogenic validation of a hyposerotonergic animal model by voluntary oral consumption of para-chlorophenylalanine
Xu et al. SERCA2 protects against cisplatin-induced damage of auditory cells: Possible relation with alleviation of ER stress
Podhorna et al. Inhibition of nitric oxide synthase reduces ultrasonic vocalizations of rat pups
Badimon Region-Specific Microglial Modulation of Neuronal Activity
Miljanović Proteomic and metabolomic signature of Dravet Syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160920

R150 Certificate of patent or registration of utility model

Ref document number: 6012726

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250